Publication: AAV2-hAADC (eladocagene exuparvovec) biodistribution and expression: Superiority of intraputaminal versus intracerebroventricular and intrathecal (lumbar) routes of administration
This research article, published in the International Journal of Toxicology, assesses alternative routes of human aromatic L-amino acid decarboxylase (hAADC) enzyme administration in monkeys by evaluating its biodistribution and expression
Learn about minimally invasive dosing options using intraputaminal, intracerebroventricular, and intrathecal administration
Compare how the routes for administration affect transgene levels in the central nervous system
Compton DR, DeMarco SJ, Yalamanchili P. Int J Toxicol. 2023;42(2):135–145
▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at email@example.com.
Eladocagene exuparvovec (UpstazaTM) is a gene therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype, currently licensed in the European Member States, Great Britain, Iceland, Liechtenstein, Northern Ireland and Norway.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any product.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2300229 | January 2024
Sign in or register to access exclusive content on this site